Britain’s industrial performance disappoints and Labour is ahead in the polls, but London index doesn’t flinch. Shire Pharmaceuticals gets FDA priority status for new dry eye disease drug. That could mean it comes to market earlier than expected. French investor Vincent Bollore spends $815 million on bulking up his stake in media conglomerate Vivendi, after activist investor P. Schoenfeld Asset Management does deal with management. Spanish banking group La Caixa eyes sale of assets including a stake in Spanish oil company Repsol. The Deal’s Jonathan Braude reports from London.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
